Favipiravir is an oral antiviral drug that has emerged as a potential treatment or prevention option for COVID-19. An international expert panel issued a weak recommendation for not using favipiravir in patients with non-severe or severe COVID-19 because of low-quality evidence. Favipiravir is not approved in Canada and is not currently accessible outside of clinical trials. Two published studies were identified in the horizon scan that evaluated the efficacy and safety of favipiravir for the treatment of COVID-19.

Link to Report

CADTH Emerging Health Technology for COVID-19: Favipiravir


Provide Feedback

Was this site helpful?

If you couldn’t find what you are looking for, please submit a request.